Syndax Pharmaceuticals Financial Results Announcement
Syndax Pharmaceuticals (NASDAQ: SNDX), a respected leader in biopharmaceuticals, is poised to present its financial results for the third quarter. The company, recognized for its innovative cancer therapies, is set to deliver these updates on November 3, 2025.
Details of the Earnings Release
The announcement regarding the financial performance will be complemented by a detailed business update. This strategic approach reflects Syndax's commitment to transparency and shareholder engagement. Management is excited to share insights about their ongoing efforts in the clinical development of groundbreaking cancer treatments.
Conference Call Information
On the day of the earnings release, Syndax will host a conference call and live audio webcast. The event is scheduled for 4:30 p.m. ET, inviting stakeholders to engage directly with the management team. Interested parties can access the webcast through the company’s Investor Relations page.
How to Join the Conference Call
For those wishing to participate in the conference call, the details are as follows:
Conference ID: Syndax3Q25
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Webcast and Replay Availability
Individuals unable to join the live call can look forward to a replay, which will be accessible on Syndax’s website approximately 24 hours post-conference. This replay will be available for 90 days, ensuring ample opportunity for stakeholders to stay informed.
Company Overview and Pipeline
Syndax Pharmaceuticals has made significant strides in the biopharmaceutical landscape, particularly with its cutting-edge cancer therapies. The company’s notable pipeline includes Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), another FDA-approved therapy targeting the CSF-1 receptor.
This pipeline showcases Syndax's dedication to reimagining cancer treatment, aiming to unlock the potential of these innovative therapies through ongoing clinical trials and research.
Connecting with Syndax Pharmaceuticals
For further details and updates, stakeholders and interested parties can visit Syndax's official website. The company encourages engagement through its social media channels, providing a platform for continual updates and interactions.
Contact Information
For inquiries or additional information, reach out to:
Sharon Klahre
Syndax Pharmaceuticals, Inc.
Email: sklahre@syndax.com
Phone: 781.684.9827
Frequently Asked Questions
1. When will Syndax Pharmaceuticals announce its Q3 results?
Syndax Pharmaceuticals will announce its third quarter financial results on November 3, 2025.
2. How can I join the Syndax conference call?
You can join the conference call by dialing the domestic number 800-590-8290 or the international number 240-690-8800, using the Conference ID: Syndax3Q25.
3. Is there a way to listen to the conference call later?
Yes, a replay of the conference call will be available on the Syndax website approximately 24 hours after the event and will remain accessible for 90 days.
4. What is included in Syndax's pipeline?
Syndax’s pipeline features several promising therapies, including Revuforj and Niktimvo™, both approved by the FDA for cancer treatment.
5. How can I contact Syndax Pharmaceuticals for more information?
You can reach out via email at sklahre@syndax.com or by phone at 781.684.9827 for any inquiries.
